25-hydroxyvitamin-d-2 and Prostatic-Neoplasms

25-hydroxyvitamin-d-2 has been researched along with Prostatic-Neoplasms* in 3 studies

Reviews

1 review(s) available for 25-hydroxyvitamin-d-2 and Prostatic-Neoplasms

Article	Year
Oncogenic osteomalacia associated with metastatic prostate carcinoma: case report and review of the literature. Journal of the American Geriatrics Society, 1993, Volume: 41, Issue:9 Topics: 25-Hydroxyvitamin D 2; Adenocarcinoma; Aged; Aged, 80 and over; Alkaline Phosphatase; Biopsy; Bone Neoplasms; Calcitriol; Humans; Ilium; Male; Osteomalacia; Phosphates; Prostatic Neoplasms	1993

Other Studies

2 other study(ies) available for 25-hydroxyvitamin-d-2 and Prostatic-Neoplasms

Article	Year
[Vitamin D deficiency increases the risk of death from prostate cancer]. Ugeskrift for laeger, 2009, Apr-06, Volume: 171, Issue:15 Topics: 25-Hydroxyvitamin D 2; Disease Progression; Humans; Male; Prostatic Neoplasms; Risk Factors; Vitamin D Deficiency	2009
Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2008, Volume: 106, Issue:3 We obtained serum bone markers and other relevant endocrine assays on 5 patients with osteonecrosis of the jaw (ONJ). The assays were C-telopeptide, N-telopeptide, bone-specific alkaline phosphatase, osteocalcin, intact parathyroid hormone, T3, T4, TSH, and Vitamin D 25 hydroxy. Diagnostic criteria for ONJ were those formulated by the American Association of Oral and Maxillofacial Surgeons. Four of our patients were women. Two had metastatic breast cancer and had been treated with zoledronic acid; one had also received pamidronate. Two others had osteoporosis and had been treated with daily alendronate. One man had metastatic prostate cancer treated with zoledronic acid. All patients had been withdrawn from bisphosphonate for at least 6 months. None were taking or had taken corticosteroids. None of the lesions had shown any significant healing and all were still causing the patients considerable distress. Yet the bone markers were within the normal range as measured in our laboratory, except for intact parathyroid hormone, which was slightly elevated in one case of metastatic breast cancer (177 pg/mL). Because the jaws have a greater blood supply than other bones, and a high bone turnover rate, bisphosphonates are highly concentrated in the jaws. This anatomic concentration of bisphosphonates might cause bisphosphonate-osteonecrosis to be manifested exclusively in the jaws and is consistent with our finding of normal serum bone markers in ONJ patients. Topics: 25-Hydroxyvitamin D 2; Alkaline Phosphatase; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Diphosphonates; Female; Humans; Jaw Diseases; Male; Osteocalcin; Osteonecrosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Peptides; Prostatic Neoplasms	2008

Article

Year

[Vitamin D deficiency increases the risk of death from prostate cancer].

Ugeskrift for laeger, 2009, Apr-06, Volume: 171, Issue:15

Topics: 25-Hydroxyvitamin D 2; Disease Progression; Humans; Male; Prostatic Neoplasms; Risk Factors; Vitamin D Deficiency

2009

Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws.

Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2008, Volume: 106, Issue:3

We obtained serum bone markers and other relevant endocrine assays on 5 patients with osteonecrosis of the jaw (ONJ). The assays were C-telopeptide, N-telopeptide, bone-specific alkaline phosphatase, osteocalcin, intact parathyroid hormone, T3, T4, TSH, and Vitamin D 25 hydroxy. Diagnostic criteria for ONJ were those formulated by the American Association of Oral and Maxillofacial Surgeons. Four of our patients were women. Two had metastatic breast cancer and had been treated with zoledronic acid; one had also received pamidronate. Two others had osteoporosis and had been treated with daily alendronate. One man had metastatic prostate cancer treated with zoledronic acid. All patients had been withdrawn from bisphosphonate for at least 6 months. None were taking or had taken corticosteroids. None of the lesions had shown any significant healing and all were still causing the patients considerable distress. Yet the bone markers were within the normal range as measured in our laboratory, except for intact parathyroid hormone, which was slightly elevated in one case of metastatic breast cancer (177 pg/mL). Because the jaws have a greater blood supply than other bones, and a high bone turnover rate, bisphosphonates are highly concentrated in the jaws. This anatomic concentration of bisphosphonates might cause bisphosphonate-osteonecrosis to be manifested exclusively in the jaws and is consistent with our finding of normal serum bone markers in ONJ patients.

Topics: 25-Hydroxyvitamin D 2; Alkaline Phosphatase; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Diphosphonates; Female; Humans; Jaw Diseases; Male; Osteocalcin; Osteonecrosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Peptides; Prostatic Neoplasms

2008